Impact of CYP26B1 Gene Variations on Drug Metabolism and Disease

Target Name: CYP26B1

NCBI ID: G56603

CYP26B1

Impact of CYP26B1 Gene Variations on Drug Metabolism and Disease

CYP26B1 (Cytochrome P450 CYP26B1 variant 2) is a gene that encodes for a protein known as CYP26B1. This protein is a key enzyme in the cytochrome P450 (CYP) family, which is responsible for metabolizing a wide variety of drugs and other substances in the body. CYP26B1 is a variant of the CYP26B1 gene, which has been shown to have altered activity in some individuals.

The CYP26B1 gene is located on chromosome 10 on the X chromosome and has been implicated in a number of pharmacological and biological processes. Studies have shown that individuals with certain genetic variations in the CYP26B1 gene, such as the variant that is being studied here, may have altered activity in the CYP26B1 enzyme and may be at risk for developing certain diseases.

One of the primary functions of the CYP26B1 enzyme is to metabolize drugs that are taken to treat a variety of medical conditions. For example, CYP26B1 is responsible for metabolizing many statins, which are used to treat high cholesterol and heart disease. It is also involved in the metabolism of other drugs, such as antidepressants and blood thinners.

The altered activity of CYP26B1 in individuals with certain genetic variations has been shown to increase the rate at which these drugs are metabolized and to lower their levels in the body. This can have a number of potential consequences, including increased risk of side effects or reduced effectiveness of the drugs.

In addition to its role in drug metabolism, CYP26B1 is also involved in a number of other biological processes in the body. For example, it is involved in the production of sex hormones, including estrogen and progesterone. It is also involved in the regulation of cell growth and differentiation, and is thought to play a role in the development and maintenance of tissues such as skin and hair.

The altered activity of CYP26B1 in individuals with certain genetic variations has also been implicated in a number of diseases. For example, individuals with certain genetic variations in the CYP26B1 gene have been shown to be at increased risk of developing certain types of cancer, such as breast cancer. They are also at increased risk of developing heart disease, high blood pressure, and other conditions.

In conclusion, CYP26B1 is a gene that encodes for a protein that is involved in a number of important biological processes in the body. The altered activity of CYP26B1 in individuals with certain genetic variations has been implicated in a number of pharmacological and biological processes, and may also be a drug target or biomarker for certain diseases. Further research is needed to fully understand the role of CYP26B1 in these processes and to develop effective treatments for individuals with altered activity of this gene.

Protein Name: Cytochrome P450 Family 26 Subfamily B Member 1

Functions: Involved in the metabolism of retinoic acid (RA), rendering this classical morphogen inactive through oxidation (PubMed:10823918, PubMed:22020119). Involved in the specific inactivation of all-trans-retinoic acid (all-trans-RA), with a preference for the following substrates: all-trans-RA > 9-cis-RA > 13-cis-RA (PubMed:10823918, PubMed:22020119). Generates several hydroxylated forms of RA, including 4-OH-RA, 4-oxo-RA, and 18-OH-RA (PubMed:10823918). Catalyzes the hydroxylation of carbon hydrogen bonds of atRA primarily at C-4 (PubMed:10823918, PubMed:22020119). Essential for postnatal survival (By similarity). Plays a central role in germ cell development: acts by degrading RA in the developing testis, preventing STRA8 expression, thereby leading to delay of meiosis (By similarity). Required for the maintenance of the undifferentiated state of male germ cells during embryonic development in Sertoli cells, inducing arrest in G0 phase of the cell cycle and preventing meiotic entry (By similarity). Plays a role in skeletal development, both at the level of patterning and in the ossification of bone and the establishment of some synovial joints (PubMed:22019272)

The "CYP26B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP26B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets